Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb combination against an undisclosed target
Molecular Target Undisclosed
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAllergy
Indication DetailsTreat allergy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today